Viral cancer therapy;La terapia viral del cáncer

Revista de Investigacion Clinica

Volumn 53, Issue 4, 2001, Pages 346-356

  Suzuki, Kaori ^a   Curiel, David T ^a  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Oncolysis; Virotherapy

Indexed keywords

ONCOLYTIC VIRUS;

ADENOVIRUS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; GENE THERAPY; GENETIC TRANSDUCTION; HERPES SIMPLEX VIRUS 1; MOLECULAR BIOLOGY; REVIEW; VIRUS REPLICATION;

ANIMALS; CLINICAL TRIALS; DNA VIRUSES; GENE THERAPY; GENOME, VIRAL; HUMANS; NEOPLASMS; RNA VIRUSES; VIRUS REPLICATION;

EID: 1642434396     PISSN: 00348376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Dock G. Influence of complicating diseases upon leukaemia. Am J Med Sci 1904; 127:563-92.
2. De Page N. Sulla scomparsa di un enorme cancro vegetante del collo dell'utero senza cura chirurgica. Ginecologia 1912; 9: 82-9.
3. Levaditi C, Nicolau S. Vaccine et Néoplasmes. Annales de L'Institut Pasteur 1923; 5: 443-77.
4. Moore AE. The destructive effect of the virus of Russian Far East encephalitis on the transplantable mouse sarcoma 180. Cancer 1949; 2: 525-34.
5. Turner JE, Mulliken B. Effects of intravenous vaccinia in mice with sarcoma 180 or leukemia 9417. Cancer 1950; 3: 354-60.
6. Southam CM, Bronstein B, Webber LF. Effect of West Nile and Ilheus viruses on mouse leukemias. Cancer Research 1951; 11: 669-75.
7. Toolan HW, Moore AE. Oncolytic effect of Egypt virus on a human epidermoid carcinoma grown in x-irradiated rats. Proc Soc Exper Biol & Med 1951; 79: 697-702.
8. Pack GT. Note on the experimental use of rabies vaccine for melanomatosis. AMA Arch Dermatol 1950; 62: 694-5.
9. Southam CM, Moore AE. Clinical studies of viruses as antineoplastic agents, with particular reference to Egypt 101 virus. Cancer 1952; 5: 1025-34.
10. Reichard KW, Lorence RM, Cascino CJ, Peeples ME, Walter RJ, Fernando MB, et al. Newcastle disease virus selectively kills human tumor cells. J Surg Res 1992; 52: 448-53.
11. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995; 1: 938-43.
12. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373-6.
13. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 1997; 57: 2559-63.
14. Russell SJ. Replicating vectors for cancer therapy: A question of strategy. Semin Cancer Biol 1994; 5: 437-43.
15. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991; 252(5007): 854-56.
16. Rommelaere J, Cornelis JJ. Antineoplastic activity of parvoviruses. J Virol Methods 1991; 33: 233-51.
17. Wildner O, Morris JC, Vahanian NN, Ford H Jr, Ramsey WJ, Blaese RM. Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer. Gene Ther 1999; 6: 57-62.
18. Doronin K, Toth K, Kuppuswamy M, Ward P, Tollefson AE, Wold WS. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J Virol 2000; 74: 6147-55.
19. Gooding LR. Regulation of TNF-mediated cell death and inflammation by human adenoviruses. Infect Agents Dis 1994; 3: 106-15.
20. Martuza RL. Conditionally replicating herpes vectors for cancer therapy. J Clin Invest 2000; 105: 841-6.
21. Kirn DH, McCormick F. Replicating viruses as selective cancer therapeutics. Mol Med Today 1996; 2: 519-27.
22. Kaplitt MG, Tjuvajev JG, Leib DA, Berk J, Pettigrew KD, Posner JB, et al. Mutant herpes simplex virus induced regression of tumors growing in immunocompetent rats. J Neurooncol 1994; 19: 137-47.
23. Jia WW, McDermott M, Goldie J, Cynader M, Tan J, Tufaro F. Selective destruction of gliomas in immunocompetent rats by thymidine kinase-defective herpes simplex virus type 1. J Natl Cancer Inst 1994; 86: 1209-15.
24. MacLean AR, ul-Fareed M, Robertson L, Harland J, Brown SM. Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence. J Gen Virol 1991; 72 (Pt 3): 631-9.
25. Kesari S, Randazzo BP, Valyi-Nagy T, Huang QS, Brown SM, MacLean AR, et al. Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant. Lab Invest 1995; 73: 636-48.
26. Yazaki T, Manz HJ, Rabkin SD, Martuza RL. Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res 1995; 55: 4752-6.
27. Andreansky S, Soroceanu L, Flotte ER, Chou J, Markert JM, Gillespie GY, et al. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res 1997; 57: 1502-9.
28. Randazzo BP, Bhat MG, Kesari S, Fraser NW, Brown SM. Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant. J Invest Dermatol 1997; 108: 933-7.
29. Kucharczuk JC, Randazzo B, Chang MY, Amin KM, Elshami AA, Sterman DH, et al. Use of a "replication-restricted" herpes virus to treat experimental human malignant mesothelioma. Cancer Res 1997; 57: 466-71.
30. Pawlik TM, Nakamura H, Yoon SS, Mullen JT, Chandrasekhar S, Chiocca EA, et al. Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus. Cancer Res 2000; 60: 2790-5.
31. Coukos G, Makrigiannakis A, Montas S, Kaiser LR, Toyozumi T, Benjamin I, et al. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy. Cancer Gene Ther 2000; 7: 275-83.
32. Toda M, Rabkin SD, Martuza RL. Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum Gene Ther 1998 10; 9: 2177-85.
33. Walker JR, McGeagh KG, Sundaresan P, Jorgensen TJ, Rabkin SD, Martuza RL. Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum Gene Ther 1999; 10: 2237-43.
34. Todryk S, McLean C, Ali S, Entwistle C, Boursnell M, Rees R, et al. Disabled infectious single-cycle herpes simplex virus as an oncolytic vector for immunotherapy of colorectal cancer. Hum Gene Ther 1999; 10: 2757-68.
35. Andreansky S, He B, van Cott J, McGhee J, Markert JM, Gillespie GY, et al. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther 1998; 5: 121-30.
36. Toolan HW, Ledinko N. Inhibition by H-1 virus of the incidence of tumors produced by adenovirus 12 in hamsters. Virology 1968; 35: 475-8.
37. Su ZZ, Luo ZY, Guo LP, Li JZ, Liu YL. Inhibitory effect of parvovirus H-1 on cultured human tumour cells or transformed cells. Sci Sin [B] 1988; 31: 69-80.
38. Cornelis JJ, Becquart P, Duponchel N, Salome N, Avalosse BL, Namba M, et al. Transformation of human fibroblasts by ionizing radiation, a chemical carcinogen, or simian virus 40 correlates with an increase in susceptibility to the autonomous parvoviruses H-1 virus and minute virus of mice. J Virol 1988; 62: 1679-86.
39. Dupressoir T, Vanacker JM, Cornelis JJ, Duponchel N, Rommelaere J. Inhibition by parvovirus H-1 of the formation of tumors in nude mice and colonies in vitro by transformed human mammary epithelial cells. Cancer Res 1989; 49: 3203-8.
40. Van Pachterbeke C, Tuynder M, Cosyn JP, Lespagnard L, Larsimont D, Rommelaere J. Parvovirus H-1 inhibits growth of short-term tumor-derived but not normal mammary tissue cultures. Int J Cancer 1993; 55: 672-7.
41. Faisst S, Guittard D, Benner A, Cesbron JY, Schlehofer JR, Rommelaere J, et al. Dose-dependent regression of HeLa cell-derived tumours in SCID mice after parvovirus H-1 infection. Int J Cancer 1998; 75: 584-9.
42. Telerman A, Tuynder M, Dupressoir T, Robaye B, Sigaux F, Shaulian E, et al. A model for tumor suppression using H-1 parvovirus. Proc Natl Acad Sci USA 1993; 90(18): 8702-6.
43. Smith RR, Huebner RJ, Rowe WP, Schatten WE, Thomas LB. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer 1956; 9(6): 1211-8.
44. Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, Mikheeva G, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998; 72: 9706-13.
45. Shinoura N, Yoshida Y, Tsunoda R, Ohashi M, Zhang W, Asai A, et al. Highly augmented cytopathic effect of a fiber-mutant E1B-defective adenovirus for gene therapy of gliomas. Cancer Res 1999 Jul 15; 59: 3411-6.
46. Boulanger PA, Blair GE. Expression and interactions of human adenovirus oncoproteins. Biochem J 1991; 275: 281-99.
47. Yu DC, Chen Y, Seng M, Dilley J, Henderson DR. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res 1999; 59: 4200-3.
48. Toyoizumi T, Tsukuda K, Sandhu AK, Odaka M, Albella SM. Amin K, et al. CEA-regulated replication-selective adenovirus for treatment of CEA-positive tumors. Mol Ther 2000; 1: S159.
49. Hallenbeck PL, Chang YN, Hay C, Golightly D, Stewart D, Lin J, et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum Gene Ther 1999; 10: 1721-33.
50. Zhang L, Peng XY, Kacinski B, Pizzorno G, Crystal R, Chung I Rutherford T, et al. L-plastin promoter confers tumor-specific gene expression and tumor-specific conditional replication competency on adenoviral vectors. Mol Med 2000; 1: S141.
51. Fueyo J, Gomez-Manzano C, Alemany R, Lee PS, McDonnell TJ, Mitlianga P, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000; 19: 2-12.
52. Suzuki K, Fueyo J, Krashykh V, Reynolds PN, Curiel DT, Alemany R. Clin Can Rex 2001; 7: 120-6.
53. Howe JA, Demers GW, Johnson DE, Neugebauer SE, Perry ST, Vaillancourt MT, et al. Evaluation of El-mutant adenoviruses as conditionally replicating agents for cancer therapy. Mol Ther 2000; 2: 485-95.
54. Balague C, Noya F, Alemany R, Gossage B, Chow L, Curiel DT. Oncolytic adenoviruses for cervical carcinoma. Mol Ther 2000; 1: S161.
55. Steinwaerder DS, Carlson CA, Li Z-Y, Ni S, Lieber A. Tumor-specific transgene expression by a replication-activated adenovirus vector. Mol Ther 2000; 1 : S18.
56. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997; 3: 639-45.
57. Wildner O, Blaese RM, Morris JC. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res 1999; 59: 410-3.
58. Freytag SO, Rogulski KR, Paielli DL, Gilbert JD, Kim JH. A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy. Hum Gene Ther 1998; 9: 1323-33.
59. Rogulski KR, Wing MS, Paielli DL, Gilbert JD, Kim JH, Freytag SO. Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization. Hum Gene Ther 2000; 11: 67-76.
60. Ganly I, Kirn D, Eckhardt SG, Rodriguez GI, Soutar DS, Otto R, et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 2000; 6: 798-806.
61. Nemunaitis J, Ganly I, Khuri F, Arseneau J, Kuhn J, McCarty T, et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial. Cancer Res 2000; 60: 6359-66.
62. Khuri F, Nemunaitis JA, Ganly I, Arsenau J, Tannock I, Romel JC, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6: 879-85.
63. Freytag S, Kim JH, Khil M, Nafziger D, Menon M, Pegg J, et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for local recurrence of prostate cancer after definitive radiation therapy. Mol Ther 2000; 1: S238.
64. Simmons JW, Mikhak B, Van der Poel HG, DeMarzo A, Rodriguez R, Goemann MA, et al. Molecular and clinical activity of CN706, a PSA-selective oncolytic Ad5 vector in a phase I trial in locally recurrent prostate cancer following radiation therapy. Mol Ther 2000; 1: S144.
65. Alemany R, Balagué C, Curiel DT. Replicative adenoviruses for cancer therapy. Nat Biotechnol 2000; 18: 723-7.
66. Hall AR, Dix BR, O'Carroll SJ, Braithwaite AW. p53-dependent cell death/apoptosis is required for a productive adenovirus infection. Nat Med 1998; 4: 1068-72.
67. Rothmann T, Hengstermann A, Whitaker NJ, Scheffner M, zur Hausen H. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J Virol 1998; 72: 9470-8.
68. Hay JG, Shapiro N, Sauthoff H, Heitner S, Phupakdi W, Rom WN. Targeting the replication of adenoviral gene therapy vectors to lung cancer cells: The importance of the adenoviral E1b-55kD gene. Hum Gene Ther 1999; 10: 579-90.
69. Harada JN, Berk AJ. p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication. J Virol 1999; 73: 5333-44.
70. Linke SP. Cancer. Has the smart bomb been defused? Nature 1998; 395: 13-5.
71. Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 1990; 50(3 Suppl): 814s-19s.
72. Schuepbach J, Sauter C. Inverse correlation of antiviral antibody titers and the remission length in patients treated with viral oncolysate: A possible new prognostic sign in acute myelogenous leukemia. Cancer 1981; 6: 1363-7.
73. Ikeda K, Ichikawa T, Wakimoto H, Silver JS, Deisboeck TS, Finkelstein D, et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med 1999; 5: 881-7.
74. Chahlavi A, Rabkin S, Todo T, Sundaresan P, Martuza R. Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice. Gene Ther 1999; 6: 1751-8.
75. Morrison LA, Knipe DM. Contributions of antibody and T cell subsets to protection elicited by immunization with a replication-defective mutant of herpes simplex virus type 1. Virology 1997; 239: 315-26.
76. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial. Gene Ther 2000; 7: 867-74.
77. Lorence RM, Katubig BB, Reichard KW, Reyes HM, Phuangsab A, Sassetti MD, et al. Regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy. Cancer Res 1994; 54: 6017-21.
78. Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N, et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000; 6: 821-5.
79. Sinkovics J, Horvath J. New developments in the virus therapy of cancer: A historical review. Intervirol 1993; 36: 193-214.
80. Webb HE, Wetherley-Mein G, Smith CE, McMahon D. Leukaemia and neoplastic processes treated with Langat and Kyasanur Forest disease viruses: A clinical and laboratory study of 28 patients. Br Med J 1966; 29: 258-66.
81. Heise C, Kirn DH. Replication-selective adenoviruses as oncolytic agents. J Clin Invest 2000; 105: 847-51.